


MDA Summer 2017 Research Grants by State



California

Jordan Blondelle, Ph.D., postdoctoral researcher at the University of California San Diego in La Jolla, was awarded an MDA development grant totaling \$180,000 over three years to increase understanding of the underlying mechanisms in **nemaline myopathy**.

Gino Cortopassi, Ph.D., professor of molecular biosciences at the University of California, Davis, was awarded an MDA research grant totaling \$300,000 over three years to optimize dosing in an FDA-approved drug called dimethyl fumarate, or DMF, in animal models of **mitochondrial myopathy** and **Duchenne muscular dystrophy (DMD)**.

Florida

Andrew Berglund, Ph.D., professor of biochemistry and molecular biology at the University of Florida in Gainesville, received an MDA research grant totaling \$300,000 over three years to develop a therapeutic strategy for both **types 1 and 2 myotonic dystrophy (DM1, DM2)**.

Illinois

Auinash Kalsotra, Ph.D., assistant professor and Beckman Fellow at the University of Illinois in Urbana, was awarded an MDA research grant totaling \$300,000 over three years to shed light on how defects develop in the heart in **type 1 myotonic dystrophy (DM1)**.

Indiana

Feng Yue, Ph.D., research associate scientist at Purdue University in West Lafayette, Ind., was awarded an MDA development grant totaling \$175,409 over three years to evaluate the therapeutic potential of a protein called phosphatase and tensin homolog (PTEN) in **Duchenne muscular dystrophy (DMD)**.

Massachusetts

Angela Lek, Ph.D., a postdoctoral research fellow at Boston Children's Hospital in Massachusetts, was awarded an MDA development grant totaling \$180,000 over three years to use cutting-edge techniques and a novel approach to search for drug targets in **facioscapulohumeral muscular dystrophy (FSHD)**.



#MDAResearch

For more information on MDA research projects, please visit mda.org/research.



MDA Summer 2017 Research Grants by State

Michigan

Andrew Lieberman, M.D., Ph.D., Gerald Abrams Collegiate Professor of Pathology at University of Michigan Medical School in Ann Arbor, was awarded an MDA research grant totaling \$300,000 over three years to test a modified antisense oligonucleotide (ASO) therapy to treat **spinal-bulbar muscular atrophy (SBMA)**.

Minnesota

Joseph Metzger, Ph.D., professor and chair of the department of integrative biology and physiology at the University of Minnesota Medical School in Minneapolis, was awarded an MDA research grant totaling \$300,000 over three years to assess different versions of shortened dystrophin protein and determine which is most stable and able to provide a functional benefit to the heart in **Duchenne muscular dystrophy (DMD)**.

Missouri

Timothy Miller, M.D., Ph.D., professor of neurology at Washington University in St. Louis, was awarded an MDA research grant totaling \$282,417 over three years to shed light on **ALS (amyotrophic lateral sclerosis)** disease mechanisms.

Nevada

Dean Burkin, Ph.D., professor of pharmacology and directory of cellular and molecular pharmacology and physiology graduate program at the University of Nevada School of Medicine in Reno, was awarded an MDA research grant totaling \$300,000 over three years to test the effects of an existing FDA-approved drug on the function of heart and skeletal muscle in a mouse model of **Duchenne muscular dystrophy (DMD)**.

Pennsylvania

Udai Pandey, Ph.D., associate professor at the Children's Hospital of Pittsburgh in Pennsylvania, was awarded an MDA research grant totaling \$300,000 over three years to identify new drugs for **ALS (amyotrophic lateral sclerosis)** caused by a mutation in the FUS gene.

Texas

James Lupski, M.D., Ph.D., D.Sc. (hon), Cullen Professor of Molecular and Human Genetics and professor of pediatrics at Baylor College of Medicine in Houston, was awarded an MDA research grant totaling \$300,000 over three years to facilitate new gene discovery and new biological insights into the pathobiology of a host of **neuromuscular diseases (NMDs)**.

France

Philippe Moullier, M.D., Ph.D., head of the Gene Therapy Institute at the French National Institute of Health and Medical Research (INSERM), was awarded an MDA research grant totaling \$300,000 over three years for preclinical work in the development of gene therapy for **Duchenne muscular dystrophy (DMD)**.



#MDAResearch

For more information on MDA research projects, please visit mda.org/research.

